<DOC>
	<DOCNO>NCT00557817</DOCNO>
	<brief_summary>Darbepoetin-alpha i.v . iron administration autologous hematopoietic stem cell transplantation hematological malignancy : prospective randomize trial .</brief_summary>
	<brief_title>Erythropoietin ( Epo ) Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation ( HSCT )</brief_title>
	<detailed_description>1 . Outline : A 3-arm prospective randomize study darbepoetin alpha administration autologous PBSC transplantation . Patients first arm receive neither darbepoetin alpha i.v . iron . Patients second arm receive darbepoetin alpha ( Aranesp ) alone start day 28 transplant . Patients third arm receive darbepoetin alpha ( Aranesp ) i.v . iron saccharate ( Venofer ) . The plan include 25 patient arm . In September 2006 , 75 plan patient include . Whereas preliminary analysis show Aranesp therapy significantly improve Hb recovery autologous PBSC transplantation , additional impact Venofer therapy remain statistically significant . However , important point , Venofer therapy could potentially improve response decrease overall cost treatment . Therefore , increase statistical power study , 50 additional patient include . Randomisation become limit arm 2 ( Aranesp ) 3 ( Aranesp + Venofer ) . 2 . Randomization : Patients randomize 1:1:1 `` Control '' , `` Aranesp alone '' `` Aranesp + Venofer '' arm . Randomization carry follow computer-generated randomization list blind personnel involve clinical care patient . Randomization carry centrally Liège fax inclusion form follow number : 32-4-3668855 . This do around day 21 post-transplant . Starting September 2006 , patient randomize 1:1 `` Aranesp alone '' `` Aranesp + Venofer '' arm , use computer-generated randomization list . 3 . Study drug administration : - Darbepoetin alpha administration : Darbepoetin alpha ( Aranesp ) administer s.c. dose 300 µg . The first dose give day 28 follow dos 2-wk interval around day 42 , 56 , 70 , 84 , 98 , 112 post-transplant . Once target Hb ( 13 g/dL ) attain , dose Aranesp reduce half 150 µg . If Hb increase &gt; 14 g/dL , Aranesp withhold resume dose 150 µg Hb decrease &lt; 13 g/dL . If Hb decrease &lt; 12 g/dL , dose Aranesp increase 300 µg . - Iron administration : Iron saccharate ( Venofer ) administer i.v . dose 200 mg ( 2 vial Venofer ) day 28 , 42 , 56 transplant . Venofer dilute 250 ml saline infuse 60 minute . Iron omit patient severe iron overload ( serum ferritin &gt; 2500 µg/L absence inflammation liver necrosis ) elevate transferrin saturation ( TS &gt; 60 % ) day 21 56 . No iron supplementation allow arm 1 . No iron supplementation allow arm 2 day 70 transplant . In arm 2 3 , patient evidence functional iron deficiency ( Transferrin saturation &lt; 20 % ) day 70 later , may receive 300 mg Venofer 90 min , minimum 2 dos . 4 . Transfusions : One red blood cell ( RBC ) unit transfuse Hb value 7.0 7.9 g/dL . Two RBC unit transfuse Hb value 7 g/dL . Platelets transfuse need , per institution 's standard . 5 . Follow-up : - Clinical follow-up : Potential toxicity associate Aranesp Venofer carefully monitor per institution 's standard . Blood pressure record around day 28 , 42 , 56 , 70 , 84 , 98 , 112 , 126 transplant . Serious adverse event ( infection , bleeding , disease progression , hospitalization ) record . In case serious adverse event judge potentially related Aranesp Venofer , principal investigator immediately notify jointly decide possible discontinuation either drug . Quality-of-life ( QOL ) evaluation carry baseline ( day 28 ) well day 70 126 transplant , i.e . 3 7 dos Aranesp therapy . This accomplished provide patient validate FACT-anemia questionnaire . The questionnaire fill patient return principal investigator . - Laboratory analysis : Complete blood count determine automate cell counter . Percentage absolute reticulocyte count obtain locally automate cytofluorometric method . Serum erythropoietin ( Epo ) level measure centrally Liège store sample commercially available radioimmunoassay ( Incstar Corp. , Stillwater , MN , USA ) . Based regression equation obtain appropriate reference subject Hct one hand log ( Epo ) , predict log ( Epo ) value derive Hct O/P ratio observed/predicted Epo value calculate . Serum soluble transferrin receptor ( sTfR ) , quantitative measure total erythropoietic activity , measure centrally Liège store sample commercially available ELISA ( R &amp; D , Minneapolis , MN , USA ) . Normal value range 3,000 7,000 µg/L . Serum iron , transferrin saturation ferritin , well standard biochemical value , measure locally standard method . On day 28 42 , 5 ml blood without anticoagulant collect centrifuge within 2 hour , serum separate 2 ml serum store -28°C . Stored sample collect local investigator finally store Liège . Serum Epo soluble TfR assay later sample simultaneously . 6 . Data collection analysis : Data collect center protocol form . The coordinate data manager Liège verify completeness accuracy data collect . The coordinate data manager responsible enter data central database . All statistical analysis perform centrally Liège .</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Inclusion criterion : Male female ; female patient must use reliable contraception method Age &gt; 16 yr &lt; 70 yr No terminal organ failure Written inform consent give patient his/her guardian minor age . Adequate iron store ( serum ferritin &gt; 100 µg/L ) day 21 posttransplant . Adequate marrow recovery , show : neutrophil &gt; 1,000/µL , platelet transfusion independence PBSC ( marrow ) transplantation Exclusion criterion : HIV positive Known allergy recombinant human erythropoietin i.v . iron saccharate Evidence active hemorrhage , hemolysis , vitamin B12 folate deficiency day 28 posttransplant ( inclusion protocol may delay day 42 problem resolve ) Uncontrolled infection , arrythmia hypertension day 28 posttransplant ( inclusion protocol may delay day 42 problem resolve ) Evidence severe iron overload ( transferrin saturation &gt; 60 % , serum ferritin &gt; 2500 µg/L day 21 posttransplant )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>HCT</keyword>
	<keyword>autologous</keyword>
	<keyword>erythropoiesis</keyword>
	<keyword>iron saccharate</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>darbepoetin alpha</keyword>
</DOC>